CC
PRVB

Corton Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Corton Capital’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,548
Closed -$94K – 399
2022
Q2 		$94K Buy
+23,548
New +$112K 0.09% 285

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corton Capital's PRVB Position: Q3 2022 in Review

Corton Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2022, closing a stake of 23,548 shares — an estimated $94K sold.

Corton Capital first reported a position in PRVB in Q2 2022 and held it in 1 quarter. The position peaked at $94K in Q2 2022. 112 funds tracked by Wall St. Rank hold PRVB as of Q3 2022.

  • Corton Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Corton Capital sold 23,548 Provention Bio, Inc. Common Stock shares in Q3 2022, an estimated $94K.
  • Corton Capital first reported a position in Provention Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Corton Capital's Provention Bio, Inc. Common Stock position peaked at $94K in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2022.

Based on Corton Capital's 13F filing for Q3 2022, filed 14 Nov 2022.